Cozaar
Product Images NDC 54868-2335

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cozaar (NDC 54868-2335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg Bottle Label)

Cozaar 100 mg (Losartan Potassium Tablets) packaging label from Physicians Total Care, Inc. The label indicates a bottle containing 30 tablets, each with a 100 mg strength. It includes dosage instructions, caution statements about child resistance, storage information, and a barcode with lot and expiration details.*

FDA Label Image

Principal Display Panel (50 mg Bottle Label)

Cozaar 50 mg (Losartan Potassium Tablets) bottle label from Physicians Total Care, Inc. The label states the strength as 50 mg and the package contains 30 tablets. It includes warnings and storage instructions, including keeping out of children's reach and storing at controlled room temperature. Manufacturing and lot details are partially visible.*

FDA Label Image

Principal Display Panel (25 mg Bottle Label)

Cozaar 25 mg medication label showing 30 tablets distributed by Physicians Total Care, Inc. The label includes lot number, expiration date, and manufacturer information (Merck Sharp & Dohme, Ltd., UK). A barcode is also present.*

FDA Label Image

Image Of Losartan Potassium Chemical Structure (Cozaar 01)

Chemical structure diagram of the active ingredient in Cozaar, labeled with potassium ion (K+). The image depicts molecular bonds and various chemical groups characteristic of the compound.*

FDA Label Image

Image Of Figure 1 (Cozaar 02)

A line graph comparing the percentage of patients with the primary endpoint over 66 months for Cozaar versus Atenolol. The graph plots time in study months on the x-axis and percentage of patients on the y-axis, showing adjusted risk reduction for Cozaar of 13% with a p-value of 0.021.*

FDA Label Image

Image Of Figure 2 (Cozaar 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over time (in months) between Cozaar and Atenolol. The graph shows a lower stroke rate for Cozaar throughout the study, indicating an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Image Of Figure 3 (Cozaar 04)

A forest plot comparing the primary composite and stroke (fatal/non-fatal) outcomes for Cozaar versus Atenolol across different patient subgroups. The chart displays hazard ratios with 95% confidence intervals for overall results, age, gender, race, presence of ISH, diabetes, and history of cardiovascular disease, indicating which treatment is favored in each category.*

FDA Label Image

Image Of Figure 4 (Cozaar 05)

A line graph comparing the percentage of patients with an event over 48 months between Cozaar and placebo groups. The graph includes a risk reduction of 16.1% with a p-value of 0.022, showing lower event rates over time for Cozaar compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.